- Policy
- The government signed an additional 40 million doses
- by Kim, Jung-Ju Apr 28, 2021 06:05am
- The government has signed an additional 40 million doses of Pfizer's COVID-19 vaccine product. As a result, Korea has secured twice the amount of vaccine vaccination in the country, enabling it to achieve the goal of forming collective immunity in November. Pan-government vaccine introduction TF (Team Leader Kwon Deok-cheol, Minister of Healt
- Company
- Roche Korea’s new NMOSD treatment Enspryng is approved
- by Eo, Yun-Ho Apr 27, 2021 06:05am
- Roche’s neuromyelitis optica spectrum disorder (NMOSD) treatment ‘Enspryng’ was approved in Korea. On the 25th, Roche Korea announced that the Ministry of Food and Drug Safety (MFDS) approved Enspryng (satralizumab) for the treatment of adults with aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NM
- Policy
- Results of HIRA’s preemptive response to COVID-19
- by Lee, Hye-Kyung Apr 27, 2021 06:05am
- In the ‘2020 sustainable management report’ published by the Health Insurance Review and Assessment Service (HIRA), the institution cited its preemptive COVID-19 response as one of its achievements last year. HIRA, which had organized a COVID-19 Countermeasure Promotion Committee in response to the COVID-19 pandemic, evaluated its perf
- Company
- MSD virtually prohibits one-on-one product presentations
- by Apr 27, 2021 06:04am
- MSD Korea has proposed new rules for one-on-one product presentations with doctors. Product presentations that are not for business purposes are minimized, and the limit for meals is lowered from &8361;100,000 per person to a maximum of &8361;70,000. It is expected that the labor-management conflict will intensify as a counter-argument has
- Policy
- The industry is paying attention to the review of generics
- by Lee, Jeong-Hwan Apr 27, 2021 06:04am
- Following the generic joint bioequivalence test '1+3 Restriction Act', the Drugs for Data-Based Re-evaluation (IMD) clinical data '1+3 Restriction Act' will be submitted to the National Assembly's Health and Welfare committee (Legislative Subcommittee) to be held next week. The two bills initiated by Democratic Party of Korea Rep. Seo You
- Policy
- Generics for Pradaxa · Xarelto are scheduled to be released
- by Lee, Tak-Sun Apr 26, 2021 05:52am
- Due to the failure of the patent challenge, sales of the domestic NOAC (oral anticoagulant drug), generic for Eliquis (Apixaban) product, will be suspended for the time being. But within this year Pradaxa (Dabigatran Etexilate Mesylate) and Xarelto (Rivaroxaban), other types of NOAC generics are expected to be released, so domestic pharmaceu
- InterView
- KRPIA will introduce advanced new drugs and seek co-growth
- by Eo, Yun-Ho Apr 26, 2021 05:52am
- The Korean Research-based Pharmaceutical Industry Association (KRPIA), which represents the multinational pharmaceutical companies that are considered the key source for the supply of new drugs, welcomed a new leader last February. KRPIA’s newly appointed Chairman Dong-Wook Oh (51) has been leading Pfizer Pharmaceuticals Korea since 2
- Company
- Hankook Korus Pharm is preparing for Sputnik V
- by Kim, Jin-Gu Apr 26, 2021 05:51am
- Hankook Korus Pharm announced on the 23rd that it has begun preliminary work for domestic approval of Sputnik V, COVID-19 vaccine developed by Russia. According to Hankook Korus Pharm, the company has recently requested documents related to the permit from the Russian Direct Investment Fund (RDIF) and is preparing the necessary materials f
- Policy
- The authorities is monitoring Sputnik V's overseas data
- by Kim, Jung-Ju Apr 26, 2021 05:51am
- Regarding the information that Cheongwadae and the licensing authorities are trying to introduce Russia's COVID-19 vaccine, Sputnik V, the Central Disease Control Headquarters said, "It is still in the stage of collecting and monitoring foreign data," and that no application for permission has been received from the company. The Central Di
- Policy
- Price cuts for Lixiana and Lenvima due to increased usage
- by Kim, Jung-Ju Apr 26, 2021 05:51am
- Prices of Daiichi Sankyo Korea’s Lixiana tab. (edoxaban tosylate hydrate), Eisai Korea’s Lenvima cap. (Lenvatinib mesilate), and Janssen Korea’s Trenfya Pre-filled Syringe inj. (guselkumab_genetic recombination) are expected to fall by 2.5% to 4.5% due to their increased usage. Prices of 10 products including Han Wha Pharma’s Hanwha Topi
